ACRIVON THERAPEUTICS INC

ACRV represents Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company. It focuses on developing precision oncology therapies using its proprietary patient selection platform, known as the Acrivon Predictive Precision Proteomics (AP3) platform. The company's lead candidate, ACR-368, is being evaluated in clinical trials for several cancer types. As a clinical-stage business, ACRV's operations center on research, drug development, and regulatory progress rather than commercial sales.

Clinical trial results, regulatory updates, and drug development timelines are among the most important drivers for ACRV. Changes in the broader biotech sector, interest rates, and general market sentiment can also influence the share price. Financing needs and cash runway updates may affect investor sentiment, while partnership or licensing news can introduce significant volatility. Because ACRV is a clinical-stage company without approved products, its stock often reacts sharply to pipeline-specific news.

The 52-week range shows the lowest and highest prices ACRV has traded at over the past year. This metric helps investors understand recent price volatility and where the current price sits relative to that range. Since the range changes daily, the most accurate figure is available on the ACRV stock page. For context, clinical-stage biotech stocks like ACRV can have wide 52-week ranges due to trial news and sector swings.

Traditional valuation metrics like the P/E ratio are often not meaningful for clinical-stage companies such as ACRV, which typically have no product revenue or earnings. Investors may instead focus on cash position, projected cash runway, pipeline progress, and the potential market size of lead drug candidates. Comparing ACRV to similar biotech peers and reviewing analyst research can provide additional context. Any valuation assessment should account for the high uncertainty inherent in drug development.

ACRV may be available for trading in pre-market and after-hours sessions through certain brokerages, though volume is often thinner and spreads can be wider than during regular hours. Extended-hours trading carries additional risks, including lower liquidity and greater price volatility. Not all brokers offer this feature, and eligibility may vary. The latest ACRV quote and any extended-hours data are shown on the stock page.

Key items to watch for ACRV include clinical trial milestones, regulatory filings and decisions, and updates on cash resources and financing activities. Changes in the competitive landscape for its target cancer indications and any partnership announcements can also matter. Because the company is clinical-stage, news flow tends to be concentrated around pipeline events. Investors can track these through company press releases, SEC filings, and the latest data on the ACRV page.